Ovid Therapeutics appoints Dr. Anna Greka to Board of Directors

Ovid Therapeutics Inc.

Board increased to seven directors, effective June 15, 2026, with appointment of Anna Greka, M.D., Ph.D. as Class III director.
Dr. Greka is Professor of Medicine at Harvard Medical School and Mass General Brigham, and holds leadership roles at Broad Institute.
She will serve on Compensation Committee and Science and Technology Committee, receiving standard non-employee director compensation.
Standard indemnification agreement entered; no related-party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anna Greka

Class III director

OVID · Ovid Therapeutics Inc.

Effective: 2026-06-15
Filed: June 3, 2026, 7:03 AM ET

On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s 2029 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anna Greka was appointed as Class III director at Ovid Therapeutics Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s 2029 annual meeting of stockholders.

View on SEC.gov

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-040038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.